FDA approves new approach to schizophrenia treatment

Main Category: Schizophrenia
Article Date: 31 Oct 2003 - 0:00 PDT

email to a friend   printer friendly   opinions  

Contact: Dan Schwartzberg
Daniels@dssimon.com
212- 736-2727
D S Simon Productions, Inc.

Long acting medication gets approval for new delivery method

More than two million Americans suffer from schizophrenia, a brain disorder that impairs the ability to think clearly, relate to others and distinguish between reality and imagination.

Missing daily medications is one of the most common problems in schizophrenia treatment and can often interfere with recovery.

As many as 75 percent of patients with schizophrenia have difficulty taking their oral medication on a regular basis. Missing medications greatly increases the risk of relapse and hospitalization.

Now the Food and Drug Administration has approved Risperdal® CONSTA™. This new long acting medication that uses advanced technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. Two week dosing can take away the worry of missed medication and can offer patients a chance to change their lives.

There is a news spot plus B-roll that features the story of a person with schizophrenia who has been able to manage her condition and regain her life while taking part in a clinical trial for this drug.

It is available at C-Band Satellite Telstar 6 Transponder 17 4040(V) on October 30 at 1:15 PM EST and October 31st 1:30PM EST

• Additional
• References
• Citations